IBI363 or Pembrolizumab with Chemo before Lung Cancer Surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two different drug combinations (IBI363 plus chemo versus pembrolizumab plus chemo) given before surgery for people with a specific type of lung cancer. The goal is to see which approach works better at shrinking the tumor and helping patients recover.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of lung cancer called non-squamous non-small cell lung cancer, and it is at a stage where surgery is possible (Stage IB, II, IIIA, or IIIB with N2 node involvement).
- Your cancer does not have an EGFR mutation or ALK gene rearrangement.
- You have not had any previous treatment for this lung cancer before surgery.
- You are healthy enough to undergo surgery, with good lung function and a good performance status (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called IBI363 given before surgery for early-stage non-small cell lung cancer. The goal is to see if it can help shrink the tumor and improve the chances of successful surgery.
This trial tests a new combination of an immunotherapy drug (IBI363) plus chemotherapy before surgery in people with Stage III lung cancer that can't be removed at first. The goal is to shrink the tumor so it can be surgically removed.
This trial tests a combination of two medicines (penpulimab and anlotinib) plus chemotherapy given before and after surgery for stage IIB-IIIB non-small cell lung cancer. The goal is to see if this approach can shrink the tumor and reduce the chance of the cancer coming back.
This Phase 2 trial tests a combination of IBI308 plus bevacizumab and pemetrexed/carboplatin given before surgery, aiming to shrink or control unresectable stage III non-small cell lung cancer. It may help some people become eligible for surgery and improve outcomes, while also testing safety and effectiveness.
This trial tests whether giving a combination of two immunotherapy drugs (ivonescimab or penpulimab) with chemotherapy before surgery helps shrink tumors and improve outcomes for people with early-stage non-small cell lung cancer. The goal is to make surgery more effective and reduce the chance of cancer coming back.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
Hear when a new Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.